 |
Immune Globulin Subcutaneous (Human) |
|---|---|
| Trade Name | Vivaglobin P (Proposed) |
| Orphan Indication | Patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access |
| USA Market Approval | USA |
| USA Designation Date | 2004-09-22 00:00:00 |
| Sponsor | CSL Behring;1020 First Avenue, P.O. Box 61501;King of Prussia, Pennsylvania, 19406 |
